List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. A Self-Replicating RNA Vaccine Against HIV-1 Delivered Using A Nanoparticle Adjuvant

    SBC: PAI Life Sciences, Inc.            Topic: NIAID

    An effective vaccine against HIV offers the best chance to stop the global epidemic but remains elusive to dateResearch has primarily focused on subunit monomerice ggpor gpor trimeric antigensthe former approachoften adjuvanted with alumhas failed in clinical trialsNative like trimers mimic the Env spike but are still poorly immunogenic and require elaborate adjuvant screening efforts to potentiat ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a Prophylactic Onchocerciasis Vaccine

    SBC: PAI Life Sciences, Inc.            Topic: NIAID

    Humanriver blindnessis caused by a filarial parasite and is a serious neglected tropical disease contributing to blindnessskin diseaseand chronic disability in the developing worldEstimates from the Global Burden of Disease Studyindicate thatmillion cases of onchocerciasisleading tomillion cases of vision impairmentoccur worldwide every yearThe goal of this project is to develop a safe and effecti ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Rational Development of a Combination Nanoparticle Adjuvant for Influenza

    SBC: HDT Bio Corp.            Topic: NIAID

    SignificanceHighly pathogenic avian H Ninfluenzawhich has killedpeople sinceis poised to cause a pandemic in a worldwide population that has no pre existing immunityCurrent Hvaccines are insufficiently immunogenic without the addition of adjuvantsbut responses to these adjuvanted vaccines are not durable and may not be protective against newly emergent viral strainsProposed solutionWe have develop ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects

    SBC: Syntrix Biosystems, Inc.            Topic: NIDA

    Fromthe utilization of the Schedule II opioids codeineOxyContin and fentanyl declined significantlydown aboutfor all three drugsIn sharp contrastthe use of tramadola Schedule IV controlled substanceincreasedSchedule IV substances have low potential for abuse and harm relative to Schedule II substancesand the fortuitous trend to tramadol has reduced the use of the relatively unsafe Schedule II opio ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Immuno Oncology Product for Multiple Myeloma: g-NK Cellular Therapy to Optimize Monoclonal Antibody Efficacy in Treating Multiple

    SBC: Indapta Therapeutic            Topic: 102

    Project Summary Abstract Multiple myeloma is the second most common hematologic malignancy in the USwith aboutnew cases in the US each yearMost patients with MM relapse and eventually become unresponsive to treatmentAlthough multiple new therapies for MM have come on the markettheir promise is limited by concerns about toxicity and low efficacyand MM remains incurableThereforethere is an urgentdem ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Translational development of specialized NK cells for cancer immunotherapy

    SBC: Indapta Therapeutic            Topic: 102

    Project Summary Abstract The annual incidence of head and neck cancers worldwide is more thancases with arounddeaths each yearand it is estimated that inthere will benew cases of non Hodgkin lymphoma with an estimateddeaths this yearIn this proposalwe describe a strategy to use a novel subset of natural killer cellsg NK cellsallogeneically for cancer therapyWe hypothesize that expansion and adopti ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Noninvasive Functional Cortical Mapping with Innovative tEEG

    SBC: CREmedical Corp            Topic: 106

    PROJECT SUMMARY Resective neurosurgery is essential for treating a range of neurologic conditions such as epilepsy and brain tumorsFor some patientswhose lesion is close to cortical language areaspostoperative expressive or receptive language deficit is a major and feared postoperative complicationMuch effort is devoted to identifying the cortical language regionsand relating such localization to ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. A multivalent, easy-to-use product to mitigate and treat radiation exposure

    SBC: FIBROPLATE, INC            Topic: NIAID

    ABSTRACTThe threat of radiological and nuclear accidents or attacks demands for effective radiation medical countermeasuresMCMable to mitigate and treat the effects of exposure to ionizing radiationsHematopoietic acute radiation syndromeHRASand cutaneous radiation syndromeCRSpose severelife threatening risks to exposed individualsCurrently no effective radio mitigatorto be administered after radia ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Production and Validation of Sj-p80 as a Veterinary Schistosomiasis Vaccine

    SBC: PAI Life Sciences, Inc.            Topic: NIAID

    Project Summary More thanbillion people are at risk worldwide for developing schistosomiasis caused by one of five species of SchistosomaTwo species that cause the most human diseaseSchistosoma japonicum and Schistosoma mansoniinfect the intestine and liver by similar processesbut differ in their geographically distributionNeither are thought to be containedand both have increased their global foo ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Clinical Evaluation of Photobiomodulation (PBM) in dry AMD Patients

    SBC: Lumithera, Inc.            Topic: NEI

    As the population continues to agedegenerative ocular diseases become increasingly common and create a tremendous burden on the health care systemAge related macular degenerationAMDrepresents a significant problem withmillion patients at risk to progress to severe vision loss in the U Salone and the prevalence of AMD is expected to double byThe dry and wet forms of the disease significantly impair ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government